Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Itraconazole and Rifampicin on HRS-1780 PK
NCT06344936Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1780 in chronic kidney disease (CKD), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 3 days, Time to Maximum Plasma Concentration at 3 days and 3 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
HRS-1780
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06344936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344936.